Company Profile
Cardiol Therapeutics Inc Stock Price, News & Analysis
- Ticker:
- CRDL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Stock performance
1.36 USD (+1.49%)
Close
Last updated: August 6, 2026
133M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRDL closed up 1.49% at $1.36. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cardiol Therapeutics is a biotechnology company focused on inflammatory heart disease and cardiology-related immunology. Its story centers on whether anti-inflammatory approaches can improve cardiac outcomes in a focused setting.
Geographic Base and Sector Classification
Cardiol Therapeutics is headquartered in Canada and listed in the U.S. market. It sits in specialty cardiology biotechnology.
Business Model Characteristics
The company depends on clinical data, translational confidence, and the ability to keep a narrow cardiovascular pipeline moving. Investors watch efficacy, safety, and proof-of-concept work.
Position Within the Biotechnology Landscape
Cardiol occupies a specialized cardio-immunology niche within biotech. The stock is catalyst-sensitive because the market needs evidence that the platform can matter in cardiac disease.
Future catalysts
CRDL is a small-cap biotech / diagnostics name with catalysts around product and pipeline updates, plus any strategic step that clarifies the company's direction. The market will care about whether there is still a viable growth path.
Recent news
- 01
Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering
Source: Cardiol Therapeutics Inc
- 02
Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering
Source: Cardiol Therapeutics Inc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cardiol Therapeutics Inc (CRDL)?
Cardiol Therapeutics Inc (CRDL) most recently closed at 1.36 USD, a +1.49% move versus the previous session.
What is the market cap of Cardiol Therapeutics Inc (CRDL)?
Cardiol Therapeutics Inc currently has a market capitalization of 133M USD on BioPharmSignal.
What does Cardiol Therapeutics Inc do?
Cardiol Therapeutics is a biotechnology company focused on inflammatory heart disease and cardiology-related immunology. Its story centers on whether anti-inflammatory approaches can improve cardiac outcomes in a focused setting.
On which exchange is CRDL stock listed?
Cardiol Therapeutics Inc (CRDL) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is Cardiol?
Cardiol Therapeutics is a biotechnology company focused on inflammatory heart disease and cardiology-related immunology.
Which conditions is Cardiol Therapeutics Inc targeting with Cardiol?
Cardiol Therapeutics Inc is associated with immunology based on its company overview and current catalyst commentary.
How does Cardiol Therapeutics Inc describe recent progress with Cardiol?
CRDL is a small-cap biotech / diagnostics name with catalysts around product and pipeline updates, plus any strategic step that clarifies the company's direction. The market will care about whether there is still a viable growth path.
What is Therapeutics?
Cardiol Therapeutics is a biotechnology company focused on inflammatory heart disease and cardiology-related immunology.